glp 1 enzyme Frontiers Glucagon-like peptide-1 receptor: mechanisms and

The latest numbers are an improvement from what we presented previously

Water, hydration, and health

The culprit is a compromised delivery system, one that oral intake alone cannot always overcome

Finerenone Finerenone is a non-steroidal mineralocorticoid receptor antagonist (contrast with spironolactone, a steroidal mineralocorticoid RA) that has been shown to reduce the risk of CKD progression (Bakris et al, 2020) and improve CV outcomes (Pitt et al, 2022) compared to placebo in randomised controlled trials in subjects with type 2 diabetes and albuminuric CKD

Photos in consistent lighting help track changes objectively

Even if youre not using medication right now, you deserve care that continues